Elicio Therapeutics, Inc. Variable Lease, Cost
Elicio Therapeutics, Inc. (ELTX) reported Variable Lease, Cost of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2023-05-10
- Elicio Therapeutics, Inc. variable lease, cost for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. variable lease, cost for the quarter ending 2022-12-31 was $98.00K, a 48.69% decline year-over-year.
- Elicio Therapeutics, Inc. variable lease, cost for the quarter ending 2022-09-30 was $108.00K, a 61.19% increase year-over-year.
- Elicio Therapeutics, Inc. variable lease, cost for the quarter ending 2022-06-30 was $91.00K, a 7.06% increase year-over-year.
- Elicio Therapeutics, Inc. variable lease, cost for fiscal 2022 was $350.00K, a 26.00% decline from fiscal 2021.
- Elicio Therapeutics, Inc. variable lease, cost for fiscal 2021 was $473.00K, a 26.78% decline from fiscal 2020.
- Elicio Therapeutics, Inc. variable lease, cost for fiscal 2020 was $646.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $98.00K derived: sum of 2 quarters · filed 2023-05-10 | $206.00K derived: sum of 3 quarters · filed 2023-05-10 | $297.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $206.00K derived: sum of 2 quarters · filed 2023-03-17 | $297.00K derived: sum of 3 quarters · filed 2023-03-17 | $350.00K 10-K · filed 2023-03-17 |
| 2022-09-30 | $108.00K 10-Q · filed 2022-11-14 | $199.00K derived: sum of 2 quarters · filed 2022-11-14 | $252.00K 10-Q · filed 2022-11-14 | $442.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $91.00K 10-Q · filed 2022-08-15 | $144.00K 10-Q · filed 2022-08-15 | $334.00K derived: sum of 3 quarters · filed 2023-05-10 | $401.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $52.00K 10-Q · filed 2023-05-10 | $243.00K derived: sum of 2 quarters · filed 2023-05-10 | $310.00K derived: sum of 3 quarters · filed 2023-05-10 | $395.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $258.00K derived: sum of 2 quarters · filed 2023-03-17 | $343.00K derived: sum of 3 quarters · filed 2023-03-17 | $473.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $67.00K 10-Q · filed 2022-11-14 | $152.00K derived: sum of 2 quarters · filed 2022-11-14 | $282.00K 10-Q · filed 2022-11-14 | $515.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $85.00K 10-Q · filed 2022-08-15 | $215.00K 10-Q · filed 2022-08-15 | $448.00K derived: sum of 3 quarters · filed 2022-08-15 | $712.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $130.00K 10-Q · filed 2022-05-16 | $363.00K derived: sum of 2 quarters · filed 2022-05-16 | $627.00K derived: sum of 3 quarters · filed 2022-05-16 | $684.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $497.00K derived: sum of 2 quarters · filed 2022-03-30 | $554.00K derived: sum of 3 quarters · filed 2022-03-30 | $646.00K 10-K · filed 2022-03-30 |
| 2020-09-30 | $264.00K 10-Q · filed 2021-11-12 | $321.00K derived: sum of 2 quarters · filed 2021-11-12 | $413.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $57.00K 10-Q · filed 2021-08-12 | $149.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $92.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |